Cytek Biosciences Inc 2025年季度报告

(Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORTHE TRANSITION PERIOD FROM TO Commission File Number001-40632_______________________________________________________ CYTEK BIOSCIENCES, INC. (Exact name of Registrant as specified in its Charter)_______________________________________________________ Registrant’s telephone number, including area code:(877)922-9835_______________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES☒NO☐Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.oIndicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒The number of shares of Registrant’s Common Stock outstanding as of April30, 2025 was126,659,196. Table of Contents PART IFINANCIAL INFORMATIONItem 1.Consolidated Financial Statements (Unaudited)3Consolidated Balance Sheets3Consolidated Statements of Operations and Comprehensive Loss4Consolidated Statements of Stockholders' Equity5Consolidated Statements of Cash Flows6Notes to Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations33Item 3.Quantitative and Qualitative Disclosures About Market Risk43Item 4.Controls and Procedures44 PART II OTHER INFORMATIONItem 1.Legal Proceedings45Item 1A.Risk Factors45Item 2.Unregistered Sales of Equity Securities and Use of Proceeds87Item 3.Defaults Upon Senior Securities88Item 4.Mine Safety Disclosures88Item 5.Other Information88Item 6.Exhibits89Signatures90 PART I - FINANCIAL INFORMATION Cytek Biosciences, Inc.Consolidated Balance Sheets Cytek Biosciences, IncConsolidated Statements of Cash Flows(unaudited) Cytek Biosciences, Inc.Notes to consolidated financial statements 1.Description of business Cytek Biosciences, Inc. (“Cytek” or the “Company”) is a leading cell analysis solutions company advancing the next generation of cellanalysis tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguishfluorescent tags on single cells (“Full Spectrum Profiling” or “FSP” technology). The Company is focused on becoming the premier cellanalysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.™® TheCompany has successfully developed and manufactured its full spectrum flow cytometry platform(“instrument(s)”or“product(s)”). The Company’s FSP cell analyzers, the CytekAurora and Northern Lights systems, deliver high-resolution, high-contentand high-sensitivity cell analysis. The Company also launched its Cytek Aurora cell sorter (“Aurora CS system”), which leverages FSPtechnology to further broaden potential applications across cell analysis. The Company’s FSP platform includes instruments, accessories,reagents, software, and services to provide a comprehensive and integrated suite of solutions for its customers.®™™ On February 28, 2023, the Company completed the acquisition of certain assets (the “FCI Acquisition”) relating to the flow cytometryand imaging business of Luminex Corporation (“Luminex”), including relating to the business of manufacturing, marketing, selling,servicing and maintaining Amnis- and Guava-branded instruments, and flow cytometry reagent products and services (the “FCIBusiness”). The acquired FCI Business includes conventional flow and image-based flow cytometry instrumentation and related productsand services (the “FCI Products”).®® The Company was incorporated in the state of Delaware in December 2014 and is headquartered in Fremont, California with offices,manufacturing facilities and distribution channels across the globe. 2.Basis of presentation and summary of significant accounting policies The Company has prepared the accompanying unaudited interim consolidated financial statements in accordance with accountingprinciples generally accepted in the United States of America (“GAAP”). Any referenc